FDA Essure Actions Draw Lawmaker Ire, Demand For Product Withdrawal
This article was originally published in The Gray Sheet
Executive Summary
While FDA has gone beyond an advisory committee recommendation to require a registry to monitor Bayer's Essure permanent contraception device, lawmakers say the agency's call for a new postmarket study and black box labeling requirements spelled out in a draft guidance are insufficient to address serious concerns with safety.